Aurobindo Pharma's subsidiary, TheraNym Biologics Pvt Ltd, has signed a master service agreement with Merck Sharpe & Dohme Singapore for contract manufacturing of biologicals. The agreement, effective May 31, 2024, will see TheraNym contract manufacturing biologicals for domestic and international markets. TheraNym will invest Rs 1,000 crore in a biologics manufacturing facility in Telangana.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.